Slide 1: Devyser Earnings call Q3 2024
Devyser Earnings call Q3 2024 October 30, 2024
Slide 2: Today's presenters
Today’s presenters Fredrik Alpsten Theis Kipling CEO CCO
Slide 3: Third quarter 2024
Third quarter 2024
Slide 4: Third quarter
Third quarter ▪ Focus on investments for future growth • Sales 48.7 MSEK (46.7 MSEK) • Growth + 4% (all organic) • Growth local currency + 7 % 4
Slide 5: Quarterly net sales
Quarterly net sales Net sales per quarter ® Net sales, SEK million SEK million 60 50 40 30 20 10 is} Dvysr.
Slide 6: Sales by region
Sales by region Q3 Q3 Q1-Q3 Q1-Q3 Q4 2023- Q4 2022- MSEK 2024 2023 Dev % 2024 2023 Dev % Q3 2024 Q3 2023 Dev % EMEA 45.2 38.9 16.3 138.0 108.8 26.8 178.6 141.1 26.6 Asia Pacific 2.1 1.6 32.9 5.5 4.3 28.9 7.3 5.1 43.4 North & South America 1.5 6.2 -76.7 9.2 10.8 -14.8 12.2 11.9 2.4 Total 48.7 46.7 4.
Slide 7: Sales by sales channel
Sales by sales channel Q3 Q3 Q1-Q3 Q1-Q3 Q4 2023- Q4 2022- MSEK 2024 2023 Dev % 2024 2023 Dev % Q3 2024 Q3 2023 Dev % Direct sales 36.7 34.8 5.3 114.6 96.9 18.2 148.5 125.4 18.4 Distributor sales 12.1 11.8 2.0 38.1 27.0 41.3 49.6 32.7 51.9 Total 48.7 46.7 4.4 152.7 123.9 23.3 198.1 158.1 25.3 7
Slide 8: Third quarter
Third quarter ▪ Focus on investments for future growth • Sales 48.7 MSEK (46.7 MSEK) • Growth + 4% (all organic) • Growth local currency + 7 % ▪ Gross margin 72% (85%) 8
Slide 9: Third quarter
Third quarter ▪ Focus on investments for future growth • Sales 48.7 MSEK (46.7 MSEK) • Growth + 4% (all organic) • Growth local currency + 7 % ▪ Gross margin 72% (85%) ▪ EBIT • -23.7 MSEK (-7.8) 9
Slide 10: Third quarter
Third quarter ▪ Focus on investments for future growth • Sales 48.7 MSEK (46.7 MSEK) • Growth + 4% (all organic) • Growth local currency + 7 % ▪ Gross margin 72% (85%) ▪ EBIT • -23.7 MSEK (-7.8) ▪ Strong financial position • 171 MSEK in liquidity • No debts 10
Slide 11: Highlights Q3 and Commercial outlook
Highlights Q3 and Commercial outlook
Slide 12: Update on Thermo Fisher Scientific
Update on Thermo Fisher Scientific ▪ In just a couple of years Devyser has become known and recognised across the transplant community ▪ Significant research work presented at ASHI ▪ First data on upcoming 2025 product launches presented at ASHI “In conclusion, direct comparison of two NGS-based dd-
Slide 13: Seeking FDA clearance with Thermo Fisher Scientific
Seeking FDA clearance with Thermo Fisher Scientific ▪ Today, patient samples are sent to external testing service providers which means that turnaround times are longer than they need to be ▪ This also means that those external service providers are collecting the revenues from the significant curre
Slide 14: North America update
▪ Devyser Genomic Laboratories in Atlanta is on track with: ▪ Getting our first tests reimbursed (Mol Dx registered, Z-codes assigned, working towards establishing coverage) North ▪ Our engagement with Cyted follows plan America ▪ Cystic Fibrosis is a key focus of ours in the the US market. With the
Slide 15: China
▪ On October 27th we received the news of our Devyser Compact product being regulatory approved by the China NMDA ▪ Since the strengthening of regulatory restrictions a few years back related to market approval our business China had been quite slow – but we’re now expecting this to resume ▪ China i
Slide 16: Rest of world update
▪ Both our direct and indirect business is following plan in both Q3 and YTD. ▪ We continue to expand market share across segments Rest of and markets world ▪ Even in Italy where we for several of our products already are the clear market leader we are delivering update double digit growth YTD and w
Slide 17: Going forward
Going forward - Focus on North America and Europe - Optimistic about sales development - Continue our way to profitability 17
Slide 18: Q&A
O&A Dvysr.
Slide 19: Connect with us
Connect with us www.devyser.com A black background with a black square Description automatically generated with medium confidence A black background with a black square Description automatically generated with medium confidence A black background with a black square Description automatically generat
Slide 20: Our diagnostic areas
Our diagnostic areas HEREDITARY DISEASES Post- Oncology Hematology Reproductive Cystic Cardiovascular transplantation Fibrosis Diseases Health
Slide 21: Product portfolio by disease area
Product portfolio by disease area Categorization HEREDITARY DISEASES Products Hereditary Hereditary Stem cell Kidney Hereditary Non-invasive Devyser CFTR breast and hematology Aneuploidy Male infertility Devyser CVD transplantation transplantation colon cancer fetal screening NGS ovarian cancer test